KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Free Cash Flow (2016 - 2026)

Esperion Therapeutics filings provide 8 years of Free Cash Flow readings, the most recent being $45.2 million for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 229.44% to $45.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.1 million, a 45.38% increase, with the full-year FY2025 number at -$13.1 million, up 45.38% from a year prior.
  • Free Cash Flow hit $45.2 million in Q4 2025 for Esperion Therapeutics, up from -$4.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $53.8 million in Q1 2024 to a low of -$89.1 million in Q1 2021.
  • Median Free Cash Flow over the past 5 years was -$36.3 million (2023), compared with a mean of -$30.6 million.
  • The widest YoY moves for Free Cash Flow: up 229.44% in 2025, down 331.5% in 2025.
  • Esperion Therapeutics' Free Cash Flow stood at -$57.7 million in 2021, then rose by 26.4% to -$42.5 million in 2022, then grew by 12.75% to -$37.1 million in 2023, then rose by 5.68% to -$35.0 million in 2024, then skyrocketed by 229.44% to $45.2 million in 2025.
  • The last three reported values for Free Cash Flow were $45.2 million (Q4 2025), -$4.3 million (Q3 2025), and -$31.4 million (Q2 2025) per Business Quant data.